Search the Newsreel

Xenia raises 2026 adjusted EBITDAre midpoint to $273M as RevPAR growth midpoint moves to 5.5%

Earnings Call Insights: Xenia Hotels & Resorts (XHR) Q2 2026 MANAGEMENT VIEW * "We are pleased to report another quarter of solid operating performance with RevPAR, adjusted EBITDAre and adjusted FFO per share modestly exceeding our expectations from when we last reported in May." …

Crexendo names Chris Aaker as chief technology officer

Crexendo, Inc. announced the appointment of Chris Aaker as Chief Technology Officer, effective August 1. Aaker, who has been with NetSapiens and Crexendo for nearly two decades, previously served as Senior Vice President of Engineering and will now oversee technology strategy and lead the …

Xenon plans Aug. 6 webcast for results and business update

Xenon Pharmaceuticals (Nasdaq: XENE) will report its Q2 2026 financial results and provide a business update on Thursday, August 6, 2026, after the U.S. markets close. A webcast and company presentation will follow at 4:30 p.m. ET. The company will likely discuss its lead …

Xencor Shares Rise After Settlement Deal With Alexion

Xencor shares increased following a settlement deal with Alexion, a subsidiary of AstraZeneca. The agreement resolves litigation related to Xencor's bispecific antibody, XmAb11516, which targets the C5 protein, the same target as Alexion's Soliris and Ultomiris. Under the deal, Xencor will pay Alexion royalties …

Xencor (NASDAQ:XNCR) Reaches New 1-Year High - Should You Buy?

Xencor (NASDAQ:XNCR) shares recently reached a new 52-week high of $21.64, closing at $21.32, marking a 10.1% gain for the session. Despite this stock performance, the company reported significant weakness in its latest quarter, with an EPS loss of $1.71 against an expected $0.75 …

Nexxen International Ltd (NEXN) CFO Sagi Niri Sells 17,578 Shares

Nexxen International Ltd's CFO, Sagi Niri, sold 17,578 shares on July 28, 2026, totaling approximately $184,744. This sale contributes to a year-long trend of insider selling with no recorded insider purchases. Despite the insider selling, the stock is considered Modestly Undervalued based on its …

Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Xenetic Biosciences Inc (XBIO) as of July 30, 2026. The company currently holds a valuation score of 8.31, ranking 140 out of 384 in its industry, with a P/E ratio of -2.14. The article notes that relevant …

Earnings call transcript: Xenia Hotels & Resorts misses Q2 2026 EPS forecast

Xenia Hotels & Resorts reported a wider-than-expected loss for Q2 2026, posting a loss of $0.21 per share against an estimated profit of $0.22, with revenue also falling short of forecasts. Despite the GAAP loss, which included a non-cash impairment charge, underlying hotel operating …

Xencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ)

Xencor (XNCR) shares rose after settling a royalty dispute with Alexion Pharma, a subsidiary of AstraZeneca (AZN). The dispute was related to Ultomiris, a rare disease therapy. Xencor had previously lowered its operating outlook in March due to this issue.

Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR)

Wedbush has reiterated an "outperform" rating for Xencor (NASDAQ:XNCR) and maintained a $26 price target, suggesting a 30.4% upside. Despite this positive outlook, the biopharmaceutical company reported weak Q1 earnings, missing revenue and EPS estimates significantly. Analyst sentiment remains mixed, with a "Moderate Buy" …

Form 4 Nexxen International Ltd. For: 30 July By Investing.com

This article reports on a Form 4 filing for Nexxen International Ltd., specifically for July 30th. Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of the company's stock. The article mentions the stock symbol …

Xenia Hotels & Resorts Releases Q2 2026 Financial Results

Xenia Hotels & Resorts announced its Q2 2026 financial results, reporting a net loss of $0.21 per share and $295.5 million in revenue, a 2.7% increase year-over-year. The company's portfolio of 30 hotels achieved a RevPAR of $207, and management guided adjusted FFO per …

Xenia Hotels & Resorts raises FY26 FFO guidance to $1.96-$2.08

Xenia Hotels & Resorts (NYSE: XHR) has increased its full-year Funds From Operations (FFO) guidance for FY26 to a new range of $1.96 to $2.08 per share, surpassing the consensus analyst estimate of $1.99. This upward revision indicates improved operational performance and suggests that …

Earnings Flash (XHR) Xenia Hotels & Resorts, Inc. Reports Q2 Revenue $295.5M, vs. FactSet Est of $302.4M

Xenia Hotels & Resorts, Inc. (XHR) reported its Q2 revenue at $295.5 million, falling short of the FactSet estimate of $302.4 million. This earnings flash also noted that the company's Q2 Adjusted FFO was $0.61 per share, just under the FactSet estimate of $0.62. …

Xenia Hotels Swings to $19.3M Q2 Loss as Hotel Rates Rise 5.7%

Earnings Flash (XHR) Xenia Hotels & Resorts, Inc. Posts Q2 AFFO $0.61 per Share, vs. FactSet Est of $0.62

Xenia Hotels & Resorts, Inc. (XHR) reported its Q2 Adjusted Funds From Operations (AFFO) at $0.61 per share, which fell slightly below the FactSet estimate of $0.62 per share. The company is a self-advised REIT focusing on luxury and upper upscale hotels across 14 …

Xenia Hotels & Resorts (NYSE:XHR) Releases FY 2026 Earnings Guidance

Xenitra (ASX:XEN) Gains as Positive Cash Flow and Higher-Margin Growth Strategy Take Shape

Xencor (NASDAQ: XNCR) to receive $105M, ending U.S. Ultomiris royalties

Xencor, Inc. has settled a commercial dispute with Alexion Pharma International Operations Limited regarding U.S. royalties on Ultomiris, agreeing to receive $105 million in two equal payments. This settlement concludes Alexion's obligation to pay U.S. royalties, while ex-U.S. royalties remain unaffected. The influx of …

Xenetic Biosciences Inc (XBIO) Institutional Confidence

Xenetic Biosciences Inc (XBIO) currently holds an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 53.00% quarter-over-quarter, now standing at 4.97%. James Simons is identified as the …

Earnings Preview: Crexendo to Report Financial Results Post-market on August 04

Crexendo Inc. (CXDO) is scheduled to announce its financial results after the market closes on August 4, 2026. The company is expected to report an EPS of $0.00, representing a 100% year-over-year increase, and revenue of $6.09 million, an 18.2% increase from the prior …

Xencor stock hits 52-week high at 21.34 USD

Xencor Inc. (XNCR) stock reached a 52-week high of $21.34, trading at $21.40, marking a significant recovery from its $6.92 low and reflecting a 154.93% surge over the past year. This growth is attributed to investor confidence in its innovative pipeline of engineered monoclonal …

Xencor Reaches $105 Million Ultomiris Royalty Settlement With Alexion; U.S. Royalties End

Xencor has settled a dispute with Alexion over U.S. royalties for Ultomiris, securing a $105 million payment. This settlement, to be paid in two installments, concludes Alexion's obligation for U.S. sales royalties, though ex-U.S. royalties will continue. The agreement became effective on July 29, …

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

Xencor, Inc. announced an agreement with Alexion Pharma International Operations Limited to resolve a commercial dispute regarding U.S. royalties for Ultomiris. Xencor will receive $105 million in two equal payments, removing Alexion's future obligation for U.S. royalties while ex-U.S. royalties remain unchanged. This resolution …

Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Xenetic Biosciences Inc (XBIO), highlighting its current risk score of 1.12, which ranks 326 out of 385 in the Biotechnology & Medical Research industry. It details the company's beta value of 2.12, indicating higher volatility compared to …

Nexxen Launches Same-Day First-Party Data Onboarding Capability in DSP

Nexxen has launched a new feature within its DSP that allows advertisers to onboard and activate first-party data within the same business day. This enhancement aims to improve campaign agility and performance by enabling faster utilization of valuable audience insights for targeting and optimization …

Xenia Hotels faces earnings test as stock hits 52-week high

Xenia Hotels & Resorts Inc. is set to report second-quarter earnings, with investors closely watching to see if the hotel REIT can justify its recent stock performance, which has seen it nearly double from its 52-week low. Analysts forecast earnings per share of 25 …

Nexxen launches 24-hour data onboarding for advertisers

Nexxen International Ltd. has launched a new first-party data onboarding capability within its demand-side platform (DSP) that allows advertisers to process their data in 24 hours or less. This global feature enables brands to ingest, validate, and prepare audiences for activation through a self-serve …

Nexxen Lets Advertisers Put First-Party Data to Work in 24 Hours

Nexxen (Nasdaq: NEXN) has introduced a new first-party data onboarding capability within its DSP, allowing advertisers to integrate, validate, and activate audience data in 24 hours or less globally. This streamlined, self-serve workflow aims to accelerate programmatic campaign activation by removing operational complexities. The …

Xencor (XNCR) Expected to Post Earnings on Wednesday

Xencor (XNCR) is set to release its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts forecasting a loss of $0.84 per share and revenue of $18.8890 million. The company significantly missed prior quarter estimates, reporting a $1.71 loss per share …

Nexxen to Announce Second Quarter 2026 Financial Results on August 12, 2026

Nexxen International Ltd. (NASDAQ: NEXN) will release its financial results for the three and six months ended June 30, 2026, before the U.S. market opens on Wednesday, August 12, 2026. The company will host a webcast and conference call at 9:00 AM ET on …

Nexxen Sets 9 a.m. ET Call to Discuss June 30 Results

Nexxen (NASDAQ: NEXN) announced that it will release its financial results for the three and six months ended June 30, 2026, before the U.S. market opens on Wednesday, August 12, 2026. The company will host a webcast and conference call at 9:00 AM ET …

Xencor Inc (XNCR) Institutional Confidence

Xencor Inc (XNCR) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The overall institutional shareholding proportion decreased by 6.84% quarter-over-quarter to 119.03%. ETHSX is the largest institutional shareholder, holding 0.75% of outstanding shares, despite a …

Xencor Inc (XNCR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Xencor Inc (XNCR), detailing its current valuation score of 6.68, which ranks it 288 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -8.70 and notes that relevant data …

Arrowstreet Capital Limited Partnership Buys 121,052 Shares of Xenia Hotels & Resorts, Inc. $XHR

Arrowstreet Capital Limited Partnership increased its stake in Xenia Hotels & Resorts (NYSE:XHR) by 4.7% in the first quarter, owning a total of 2,677,259 shares valued at $39,704,000. Several other institutional investors also adjusted their positions in XHR. Analysts have given Xenia Hotels & …

Xenora Minerals (ASX:XRA) Refocuses on Gold and Critical Minerals Strategy as Exploration Progress Remains Key